Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study

被引：0
|
作者：
Li Ying
Ji Suyun
Liang Yanhua
Liang Yunsheng
Deng Li
Dang Lin
Lv Chengzhi
Lin Bingjiang
Zhang Furen
Shi Wendi
Li Jinnan
Dong Yu
Dou Guanshen
Yuling Shi
机构：
[1] Tongji University School of Medicine,Department of Dermatology, Shanghai Skin Disease Hospital
[2] Southern Medical University,Department of Dermatology, Dermatology Hospital
[3] Southern Medical University,Department of Dermatology, Cosmetology and Venereology, Shenzhen Hospital
[4] Longgang Central Hospital of Shenzhen,Department of Dermatology
[5] Dalian Skin Disease Hospital,Department of Dermatology
[6] Ningbo First Hospital,Department of Dermatology
[7] Shandong First Medical University & Shandong Academy of Medical Sciences,Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology
[8] Eli Lilly and Company,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Efficacy; Ixekizumab; Psoriasis; Real world; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：5464 / 5474
页数：10
相关论文
共 50 条
  • [31] Racial/ethnic differences in treatment efficacy and safety for moderate-to-severe plaque psoriasis: a systematic review
    Ferguson, Jessica E.
    Seger, Edward W.
    White, Jacob
    McMichael, Amy
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2023, 315 (01) : 41 - 50
  • [32] Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis
    Yahiya Y. Syed
    American Journal of Clinical Dermatology, 2017, 18 : 147 - 158
  • [33] Racial/ethnic differences in treatment efficacy and safety for moderate-to-severe plaque psoriasis: a systematic review
    Jessica E. Ferguson
    Edward W. Seger
    Jacob White
    Amy McMichael
    Archives of Dermatological Research, 2023, 315 : 41 - 50
  • [34] Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis
    Syed, Yahiya Y.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2017, 18 (01) : 147 - 158
  • [35] Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
    Gisondi, Paolo
    Girolomoni, Giampiero
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 1763 - 1770
  • [36] Ixekizumab: A Review of Its Use for the Management of Moderate to Severe Plaque Psoriasis
    Shelton, Sydney K.
    Bai, Sandra R.
    Jordan, Joseph K.
    Sheehan, Amy Heck
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (03) : 276 - 284
  • [37] Real-world efficacy and safety of apremilast monotherapy in the management of moderate-to-severe Psoriasis
    Shah, Bela J.
    Mistry, Deval
    Chaudhary, Navin
    Shah, Shikha
    INDIAN DERMATOLOGY ONLINE JOURNAL, 2020, 11 (01) : 51 - 57
  • [38] Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis
    Al Sawah, Sarah
    Foster, Shonda A.
    Burge, Russel
    Amato, David
    Schacht, Alexander
    Zhu, Baojin
    Hartz, Susanne
    Leonardi, Craig
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (12) : 1224 - 1230
  • [39] Effectiveness of Ixekizumab in Elderly Patients for the Treatment of Moderate-to-Severe Psoriasis: Results From a Multicenter, Retrospective Real-Life Study in the Lazio Region
    Dattola, Annunziata
    Bernardini, Nicoletta
    Caldarola, Giacomo
    Coppola, Rosa
    De Simone, Clara
    Giordano, Domenico
    Giunta, Alessandro
    Moretta, Gaia
    Pagnanelli, Gianluca
    Panasiti, Vincenzo
    Persechino, Severino
    Potenza, Concetta
    Trovato, Federica
    Zangrilli, Arianna
    Bianchi, Luca
    Pellacani, Giovanni
    Peris, Ketty
    Richetta, Antonio Giovanni
    DERMATOLOGY PRACTICAL & CONCEPTUAL, 2024, 14 (03):
  • [40] Ocular manifestations in moderate-to-severe psoriasis in India: A prospective observational study
    Kharolia, Anjali
    Parija, Sucheta
    Moharana, Bruttendu
    Sirka, Chandra Sekhar
    Sahu, Sandip Kumar
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2022, 70 (09) : 3328 - 3332
12345